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Summary
Introduction: Early diagnosis of leprosy, including the diagnosis of sub-clinical
disease in contacts of known cases, would be a major advance. The signs of early
leprosy are often difficult to assess and a reliable diagnostic test could play an
important role in identifying cases and thus reducing transmission.
Methods: Subjects were recruited at Centro de Sau´de Jardim Guanabara,
Rondono´polis, Mato Grosso State, Brazil. Sera were obtained from 174 recently
diagnosed leprosy patients, 409 household contacts, 53 endemic controls and 12
patients with active TB. 186 of the household contacts were re-tested on subsequent
visits. Both the NDO-LIDw rapid test (Orange Lifew, Rio de Janeiro, Brazil) and an
anti-PGL-1 ELISA test were used on all samples for comparison.
Results: LID-1 was positive in 25 of 125 PB cases (20%), but in 41 of 49 MB cases
(83·7%), while the anti-PGL-1 ELISA was positive in 8 (6·4%) and 35 (71·4%) cases,
respectively. Specificity for LID-1 was 85% and for the anti-PGL-1 ELISA, 97%.
Amongst household contacts, 9 of 409 (2·2%) were positive on the LID-1 test, and
a further 51 (12·5%) were weakly positive; although 9 cases of leprosy were
subsequently identified amongst these contacts, 6 had tested negative, 2 were weakly
positive and only 1 had been positive.
Conclusion: The ND-O-LID-1 assay can be easily performed by the addition of
serum to the assay device, and thus can be applied in resource-poor settings. The test
was found to be useful for the detection of multibacillary cases, which in the long
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term will help to reduce transmission of the disease. This is a specific test, but it is not
very sensitive for early detection of leprosy in household contacts and paucibacillary
forms.
Introduction
Leprosy is a chronic infectious disease with a wide spectrum of clinical forms. Until now
there has not been a gold standard diagnostic test for leprosy, and its detection is mostly based
on clinical signs and symptoms. According to the clinical spectrum, leprosy patients are
classified as: tuberculoid (TT), borderline-tuberculoid (BT), mid-borderline (BB), borderline-
lepromatous (BL), and lepromatous (LL).1 The World Health Organization suggested a
clinical classification to select the treatment regimen based on the number of skin lesions,
bacterial positivity by slit skin smear and number of involved nerves.2 This system classifies
leprosy in two simplified categories: multibacillary (MB) leprosy (typically smear positive, or
having more than one nerve involved or more than five skin lesions) and paucibacillary (PB)
leprosy (smear negative, none or one nerve involved, maximum of five skin lesions).
Hyper-endemic areas and the high incidence of leprosy3 remain a cause for concern to the
Leprosy Control Programme in Brazil. In addition, it has been shown that the earlier a leprosy
patient is diagnosed and treated, better the outcome of the disease.4 In these endemic areas,
sensitive and specific diagnostic laboratory tests would be of great use in the detection of
leprosy at an early stage of the disease, or detection of disease during the evaluation of
contacts.5 Serum antibodies levels against phenolic glycolipid-1 (PGL-1), a specific M. leprae
cell wall antigen6,7 has been used in both enzyme-linked immunosorbent assay (ELISA) and
rapid lateral-flow (LF) test formats, however, both showed limited sensitivity in the detection
of PB leprosy.6,8,9 Nonetheless, anti-PGL-I response is strong among MB patients and reflects
the bacillary load in leprosy patients.10
In 2006, Reece et al.,11 described two novel antigenic proteins (ML0405 and ML2331)
that clearly differentiated MB patients from healthy and M. tuberculosis-infected control
individuals in endemic areas. Therefore, these antigens appear suitable for the development
of serologic tests for leprosy. LID-1, a fusion of the ML0405 and ML2331 proteins, has
proven to be strongly reactive with MB patients sera in many geographic locations.12 – 14
Also, a previous study suggested that the addition of LID-1 protein to PGL-I could improve
sensitivity in a diagnostic test, since some patients lacking anti-PGL-I antibodies have
antibodies that recognise LID-1, and vice versa.13 Thus, given the challenges of developing a
diagnostic assay, a simple and rapid test is currently produced and commercialised in Brazil.
It incorporates both the LID-1 and PGL-I antigens, immobilised on a nitrocellulose
membrane for antibody detection in sera, requiring minimal personnel training for leprosy
diagnosis.15
Leprosy is an insidious disease and it is very difficult to rely on clinical examination
for early detection of the disease. Therefore, the validation of this recently developed
commercial test would be useful for early leprosy diagnosis. In this work, carried out in a
highly endemic area in Midwestern Brazil, we proposed to apply this rapid test in leprosy
patients and their household contacts during 5 years of follow-up.
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Material and Methods
SUBJECTS AND SAMPLES
This study was carried out in two phases: at diagnosis of leprosy patients (2009–2010) and
follow-up of household contacts (2009–2014). Thus, between 2009 and 2010, leprosy
patients (MB and PB), household contacts, endemic controls and pulmonary tuberculosis
individuals were recruited at Centro de Sau´de Jardim Guanabara, Rondono´polis, Mato
Grosso State (Midwestern Brazil). All patients signed the informed consent forms, approved
by the Ethics Committee of the Federal University of Sa˜o Paulo (Protocol number 26803).
Sera were obtained from 174 (78 female/96 male) recently diagnosed leprosy patients (LP),
409 (228 female/181 male) household contacts (HHC) and 53 (36 female/17 male) endemic
controls (EC). We excluded patients with leprosy reactions. Patients were classified by
bacterial, histological, and clinical observations carried out by qualified personnel, with the
bacillary index (BI) of the skin biopsies recorded at the time of diagnosis (07 LL, 12 BL, 30
BB, 63 BT, 43 TT, 19 I). We also included 12 (07 female/05 male) tuberculosis (TB) patients
to evaluate potential antigen cross-reactivity. Sera from TB patients were obtained after
drawing blood from Mycobacterium tuberculosis sputum-positive, human immunodeficiency
virus-negative individuals with clinically confirmed pulmonary TB who were undergoing
treatment. All serum specimens were aliquoted and stored at2208C or2808C. From 2009 to
2014 the household contacts were contacted by telephone or via the Health Unit and invited to
be re-evaluated. From the total, 186 individuals were examined two or three times and blood
was collected for serology.
SEROLOGICAL ASSAYS
NDO-LIDw rapid test
The NDO-LIDw rapid test (Orange Lifew, Rio de Janeiro, Brazil) was developed by
impregnating nitrocellulose membranes with ND-O-LID-1, a conjugation of the ND-O (a
synthetic mimetic of PGL-I disaccharide) and the LID-1 protein.12,15 The NDO-LIDw test is
provided as a ready-to-use kit to be performed by adding undiluted serum to be tested (10ml)
and two drops of running buffer into the sample well, causing the migration of the sample and
colloidal gold beads loaded with anti-IgG and anti-IgM antibodies through the membrane and
across a detection window. Interactions with the test and/or control lines are revealed as a red
colour. Readings were performed 20 minutes after buffer addition.
Visual readings were performed by three independent readers. The results required the
visualization of a clear control line in the detection window. A positive result was defined by
the staining of both the control line and the test line (visual reading scores: 1þ /2þ /3þ ). Faint
test line staining was considered as a weakly positive (score 0·5þ ) result, and it was
considered a positive test response throughout the entire analysis. No test line staining was
considered as a negative result.
ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA)
Briefly, the wells of ELISA plates were coated with either the semi-synthetic antigen PGL-I-
ND-O-BSA (natural disaccharide coupled to bovine serum albumin through an octil group
provided by John Spencer, Colorado State University, USA) (50 ul per well of 100 ng/ml
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carbonate buffer, overnight at 48C) or with coating buffer (control). After blocking with 1%
milk-PBST (phosphate buffered saline tween 20), a dilution of each sample equivalent to
1:500 serum in PBST containing 10% normal goat serum (NGS) was included (50 ul per well,
378C, 60 min) in four wells (duplicates of antigen coated and buffer coated). The plates were
washed with PBST and incubated with 1:10,000 dilution of peroxidase-conjugated rabbit anti-
human IgM/HRP (DAKOw, Denmark) in PBST-10% NGS (50 ul per well, 378C, 60 min).
After another wash, the colour reaction was developed with 50 ul of substrate solution
containing O-phenylenediamine added to the wells (at room temperature for about 20 min).
The reaction was stopped with 50 ul of 2·5 N H2SO4 and the absorbance was read at 490 nm.
The mean absorbance of the BSA control wells was subtracted from that of the wells with ND-
O-BSA, and the result was regarded positive if the optical density (OD) exceeded 0·150 (the
mean absorbance plus three standard deviations of 100 healthy Brazilian control subjects).
STATISTICAL ANALYSIS
Differences in antibodies anti-ND-O-BSA and anti-ND-O-LID-1 levels between test groups
were analyzed with the two-tailed Mann-Whitney and Kruskal Wallis tests for non-
parametric distribution using GraphPad Prism version 5·01 for Windows (GraphPad
Softwarew, version 5, USA). Pearson’s correlation was used to calculate r2 for ND-O-BSA
versus ND-O-LID-1, and Spearman correlation was used to calculate r2 for BI versus ND-
O-LID-1, using GraphPad Prism version 5·01. Moreover, the sensitivity, specificity, positive
and negative predictive values (PPV and NPV) were determined with 95% confidence
interval (CI). Results were considered statistically significant for P values ,0·05.
Results
We analysed sera using both the ELISA leprosy test (based on the detection of IgM antibodies
against the PGL-I mimetic ND-O-BSA antigen) and the ND-O-LID-1 rapid diagnostic test
(based on the detection of IgM antibodies against ND-O and IgG antibodies against the LID-1
I TT BT BB BL LL HH
C EC TB
0.00
0.15
0.30
0.45
0.60
0.75
0.90
1.1
1.2
a b
PG
L-
1 
(D
.O
.)
I TT BT BB B
L LL
HH
C EC TB
0
1
2
3
4
0,5
N
D
-O
-L
ID
-1
 (S
co
re 
va
lue
)
Figure 1. Distribution of antibody responses among participants. (a) IgM antibodies to phenolic glycolipid-1 (PGL-1)
by ELISA, presented in optical density (OD). The traced horizontal line is the cut-off (OD $ 0·150). (b) IgM/IgG
antibodies to synthetic disaccharide glycolipid ND-O and to Mycobacterium leprae protein leprosy IDRI diagnostic-1
(LID-1) by imunodot tests, presented by visual reading of NDO-LIDw test scored (0 ¼ absent test line, positive
result ¼ 0,5,1,2,3þ). Data grouped by clinical forms of leprosy patients groups (I, TT, BT, BB, BL, LL), endemic
control (EC), household contact (HHC) and tuberculosis patients (TB).
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protein) to permit comparisons between these tests. The distribution of anti-PGL-I and
anti-ND-O-LID-1 antibodies levels in sera of individuals from the different groups is
demonstrated in Figure 1. In this study, among the MB leprosy (BB, BL and LL), the visual
reading results indicated that ND-O-LID-1 tests produced a clear strong band.
Comparing the two serological test, the Pearson’s correlation for MB was r2 ¼ 0·7934.
Correlation of r2 ¼ 0·5178 was determined among PB patients (I, TT and BT). Comparing
these assays for all leprosy patients a correlation of r2 ¼ 0·8444 was found, indicating good
agreement in respect to serological status of the samples. The Spearman’s correlation
between bacterial index (BI) and antibodies against the ND-O-LID-1 resulted in r2 ¼ 0·7382
for MB leprosy patients and r2 ¼ 0·1654 for PB leprosy (data not shown).
Among 174 leprosy patients with diagnosis confirmed by clinical and Ridley and
Jopling’s histopathology classification, 22 (12·6%) weak positive results were found using the
rapid test (Table 1).
The results of anti-PGL-I ELISA and ND-O-LIDw were not always concordant (either
positive, negative or weak positive) and three patients with Indeterminate leprosy were
identified and presented with positive PGL-I: two ND-O-LID-1 positive and one ND-O-LID-
1 weak positive. Among the five BT PGL-I positives, four were ND-O-LID-1 positive and
one weak positive. The majority of the sera among 18 BB PGL-I positive patients were ND-
O-LID-1 positive (n ¼ 16) and two ND-O-LID-1 weak positive. However, in the BB group
three PGL-I negative with two ND-O-LID-1 positive and one ND-O-LID-1 weak positive
Table 1. Serum detection of anti-ND-O-LID-1 IgG/IgM (ML0405 and ML2331 associated to ND-O) antibodies by
immunodot and e anti-PGL-I (ND-O) IgM using ELISA, in 174 leprosy patients, classified according to Ridley and
Jopling or Madrid’s, with inclusion of the indeterminate group
NDO-LID-1 results PGL-I results
Clinical Form (Sample n.) Negative 0·5þ 1þ 2þ 3þ Pos Neg
I (19) 14 03 02 0 0 3 16
TT (43) 37 06 0 0 0 0 43
BT (63) 49 07 06 01 0 5 58
BB (30) 08 04 11 04 03 18 12
BL (12) 0 02 01 06 03 10 02
LL (07) 0 0 01 03 03 7 0
Total (174) 108 22 21 14 09 43 131
Table 2. Sensitivity, specificity, positive predictive values (PPV) and negative predictive values (NPV) for the NDo-
LID-1 and PGL-1 (serological evaluation)
NDO-LID1 (%) PGL-1 (%)
leprosy MB leprosy PB leprosy leprosy MB leprosy PB leprosy
Sensitivity 37·93 83·67 20 24·71 71·43 6·4
Specificity 85·33 85·33 85·33 96·82 96·82 96·82
PPV 52·38 40·59 29·41 76·79 72·92 38·1
NPV 76·37 97·76 77·73 75·14 96·59 77·19
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were found. Anti-PGL-I and anti-ND-O-LID-1 antibody levels varied significantly between
patients and EC, HHC and TB (P , 0·05). No significant difference was found for EC, HHC
and TB for both serological tests.
The sensitivity of ND-O-LID-1 test for leprosy patients was higher (37·93%) than the
PGL-I ELISA test (24·71%). The sensitivity of the anti-ND-O-LID-1 was higher for MB and
PB patients, compared to anti-PGL-I test. Specificity was high for both tests. On the other
Table 3. Serum positivity of anti-ND-O-LID-1 rapid test and anti-PGL-I ELISA in 409 household contacts of leprosy
patients, including the household contacts that were diagnosed with the disease
HHC of leprosy patients ND-O-LID-1 Test results
PGL-I ELISA
Test results
N8 sample Neg Pos Weak pos Neg Pos
LL HHC (12) 12 – – 12 –
BL HHC (50) 46 1 3 49 1
BB HHC (64) 56 1 7 63 1
BT HHC (144) 119 3 22 138 6
TT HHC (92) 79 3 10 88 4
I HHC (47) 37 1 9 46 1
Total/group 409 349 9 51 396 13
HHC: Household contact; LL: lepromatous; BL: borderline-lepromatous; BB: borderline-borderline; BT:
borderline-tuberculoid; TT: tuberculoid; I: indeterminate; Pos: positive; Neg: negative.
Table 4. Serological evaluation of the semi-quantitative ND-O-LID-1 rapid test and ELISA PGL-I test, in household
contacts of leprosy patients during 5 years of follow-up, Rondono´polis-MT, Brazil. Household contacts were
categorized by social distance from the index patient
HOUSEHOLD CONTACTS BECAME PATIENTS 2009–2011
N8 HHC Clinic Kith and Kin ND-O-LID-1 Test PGL-I ELISA Index Case Clinic
1 BT son 0·5þ 0·004 TT
2 TT wife neg 0·012 TT
3 I daughter neg 0·030 BT
4 TT daughter neg 0·005 LL
5 BT son neg 0·053 LL
6 TT son neg 0·074 TT
7 I husband neg 0·030 BB
8 BT mother 0·5þ 0·028 BT
9 BT brother 1þ 0·236 BT
HOUSEHOLD CONTACTS BECAME PATIENT 2012–2014
N8 HHC Clinic Kith and Kin ND-O-LID-1 Test PGL-I ELISA Index Case Clinic
1 BB son 0·5þ 0·011 BT
2 BT husband 0·5þ 0·050 BT
3 TT grandson neg 0·038 BL
4 BB brother neg 0·068 BL
5 BT grandmother 1þ 0·075 BT
6 BT mother Neg 0·012 TT
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hand, PPV was higher for the PGL-I ELISA than ND-O-LID-1 in leprosy patients. Both tests
showed high NPV for leprosy and also for MB and PB patients (Table 2).
During initial evaluation of household contacts nine out of 409 contacts (2·2%) were
diagnosed with leprosy, while 51 (12·5%) had weak positive results in the rapid test (Table 3).
The serological positivity responses among HHC was low to anti-PGL-I ELISA and anti-
ND-O-LID-1 with result 1þ , (3·2% and 2·2% respectively), in the first evaluation. Among
these contacts, 349 individuals were ND-O-LID-1 negative and six of them became patients
(2I, 3TT, 1BT); from the nine individuals ND-O-LID-1 positive, one became a patient
(BT 1þ ) and among 51 individuals with weak positive ND-O-LID-1 result, two became
patients (BT). One contact who developed BT leprosy presented positive ND-O-LID-1 and
PGL-I ELISA test (OD . 0·150). Good correlation value was found for ND-O-LID1 and
PGL-1 ELISA (r2 ¼ 0·7717) in HHC, EC and TB samples.
During the follow-up 25 household contacts were re-evaluated twice and 161, once.
Among the 186 household contacts, 29 (17·16%) showed at least one initial positive
serological exam. Positivity was repeated in 12 individuals at the second or third evaluations;
however, they did not show any signs of leprosy during the remainder of the study. Six
household contacts who attended on their own initiative at the Health Centre were diagnosed
with leprosy, and only three of them presented positive serology at diagnosis (Table 4).
HHC also responded to the M. leprae anti-PGL-I ELISA (3·1% positivity) and rapid test
ND-O-LID-1 (14·6% positive, including weak reaction). Amongst HHC, nine were diagnosed
with leprosy almost at the same time as the index case. And among them, six were ND-O-
LID-1 negative (2I, 3TT, 1BT), two weak positive (BT) and one positive (BT 1þ ).
From the EC, 51 individuals presented ND-O-LID-1 negative results and two of them
showed weak positive test to ND-O-LID-1 resulting in specificity of 96·2%. The anti-PGL-I
ELISA results were negative for all EC individuals. All the TB patients also presented
negative results to both ND-O-LID-1 and PGL-I ELISA test.
Discussion
The World Health Organization set a global target reduction of Grade-2 disability in new
cases at $35% by the end of 2015 compared to baseline levels recorded at the end of year
2010.16 To achieve this goal, the leprosy control programmes would need to reduce the delay
in disease diagnosis, administer MDT promptly, ensure that patients fully completed their
treatment and confirm, during follow-up, that patients were cured. Together, these actions
should impact in the transmission of M. leprae in the community and decrease the cases with
disability.
Besides that, a tool for identifying leprosy cases (asymptomatic and any symptomatic
form of leprosy) was identified as a prerequisite to elimination, thereby addressing the goals
of the 2020 targets of the London Declaration on Neglected Tropical Diseases.17,18 Thus, in
order to achieve this goal, studies are ongoing to develop a serological test that could be easily
used in the field to identify those individuals at highest risk of acquiring leprosy. Such a test
would improve early diagnosis and potentially break the chain of transmission to help Grade-
2 disability rate reduction, besides facilitating the health workers during their evaluation of
suspected cases.
In this context, recently, a lateral flow test based on IgM and IgG antibodies detection
against the ND-O-LID-1 conjugate was developed. It provides results within 20 minutes of
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sample addition, and has shown strong antibody responses in BB/BL/LL cases (87%),15,19
similar to the present study showing 83·6% of positivity for MB cases. According to Cardoso
et al. (2013)15 the seropositivity of the ND-O-LID-1 test varied across the spectrum of
leprosy: 97·4% for LL, 83·7% BL and 76·9% for BB patients. A similar distribution of
positivity across the MB leprosy spectrum enrolled in the present study, varying from 100%
for LL and 100% BL, to 73·3% for BB; also, when patients were compared with non-diseased
individuals, the BB, BL and LL patients had significantly higher antibody titers against both
anti-PGL-I ELISA and ND-O-LID-1. In the present study, the responses to ND-O-LID-1 and
anti-PGL-I ELISA in PB individuals were weak, 20% and 6·4%, respectively. These results
confirm other work in which leprosy IDRI diagnostic-1 (LID-1) and ND-O-BSA antigens
used in combination appear to have utility as a biomarker for LL/BL leprosy forms
(NDO-LID).20
It is worth commenting that 12·2% of the samples from MB cases and 12·8% from PB
patients resulted in ND-O-LID-1 weak positive. The manufacturer of the ND-O-LID-1 test
suggests that tests with weak positive results should be considered negative, nevertheless, the
weak positive result indicates that the patients may have antibody levels close to the threshold
level of a positive result. This may be true for PB patients that have low bacillary loads, or
even in early infection, in which the stimuli to IgG production against ND-O-LID-1 or IgM
against PGL-I were not high enough to confirm diagnosis of leprosy. The antibody response
of a weak positive result to ND-O-LID-1 was considered positive in order to achieve the goal
of reducing the delay in disease diagnosis. In addition, the weak positive ND-O-LID-1 could
help to improve the accuracy of the clinical assessment, since in the present study 22 patients
showing weak positive test results (that otherwise would be considered negative by the
manufacturer’s instructions) indeed had a leprosy diagnosis confirmed.
Within the EC studied, specificity of 96·2% was calculated and corroborated the 97·4%
specificity demonstrated by Duthie et al. (2014).19 The present study showed that among 53
EC, 51 presented negative ND-O-LID-1 results and two weak positive results, while all EC
were negative for anti-PGL-I ELISA. The weak positive results suggest that individuals are
infected with M. leprae, however, depending on their immune status, they will either evolve
to disease, or else be able to control the infection before appearance of signs and symptoms.
When household contacts that became sick were distributed by inter family relationship,
most of them were children (40·0%) or partners (20·0%) of the index case. These results
corroborate the results of Dessunti et al.21 which showed 40·6% of children and 27·8%
partners with disease among 1055 leprosy cases and 3394 household contacts in Londrina-
PR, Brazil. In the present study children prevailed over partners and siblings as the most
exposed relatives. The most frequent sources of infection were mothers and grandparents who
constituted the relationship in 20% of the samples evaluated.
Matos22 notes that 11·19% of contacts in his study were already sick at the time of clinical
evaluation and 14·29% were diagnosed during the follow-up. Douglas et al.,23 however,
reported that 33 new cases emerged among 559 contacts (27 cases during 5 years active
surveillance and six cases during 10 years passive surveillance) in Cebu. In the present study
2·2% of the contacts had leprosy in the initial evaluation, while six among 186 HHC (3·2%)
became sick during five years of follow-up. Similar results were obtained by Goulart et al.,24
in Uberlaˆndia-MG, Brazil, showing 2·0% of contacts with disease, 75% in the first year of
surveillance. Also, the work of Amorin et al.,25 showed that 332 HHC were followed and
among those 12 (3·6%) were diagnosed with leprosy in a median time of 31 (3–79) months
after recruitment, six of them presented with MB leprosy. In the present study, as a final result
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15 (3·67%) HHC became sick, being 85% with PB leprosy. Interestingly, most of them were
contacts of PB patients which suggests there is another source of infection in the surrounding
family. As a control strategy, it is import to widen the concept of HHC to social or
neighbourhood contacts, as they may be active players in the transmission chain.
Duthie et al. showed that IgG antibody response to ND-O-LID-1 was detected one year
earlier than appearance of leprosy symptoms in seven out of 11 HHCs of MB patients (64%).
The IgG response was strikingly more elevated and occurred much earlier than the increases in
the anti-PGL-I IgM responses in the same individuals.12 In the present study, this was not
observed because most of the HHC that became sick were PB. This favours the idea that there
may be a source of infection (undiagnosed MB) around the individual with positive serological
exam, and supports the importance of evaluating contacts as a control measure for the disease.
Potential cross-reactivity is an important issue to be considered in the development of a
new serologic test for leprosy, particularly for countries with a high incidence of TB, high
BCG vaccination coverage and high levels of exposure to environmental mycobacteria. Thus,
the ND-O-LID-1 negativity among TB and EC indicates that even with the previous BCG
vaccination, there is no cross reactivity with the new rapid test. This indicates the high
specificity of the test, so cross-reaction between M. tuberculosis and other mycobacterial
antigens is not a significant concern.
Thus, the present data demonstrate not only the utility of the rapid test ND-O-LID-1 in
detecting MB leprosy patients compared to control subjects, but also suggests exposure to or
potential asymptomatic infection with M. leprae, reinforcing the findings of Cardoso et al.,15
Bobosha et al.,26 and Wen et al.27
The results of the present study showed good correlation between the two serological tests
for confirmed leprosy cases, however, there were more ND-O-LID-1 positive tests than PGL-
I positive, demonstrating higher sensitivity of the rapid test, that may be due to the presence
of one glycolipid and two protein antigens in the ND-O-LID-1 that would be capable of
detecting both, IgM and IgG antibodies. In spite of that, these results do not corroborate the
statement that individuals with positive serology show eight times higher risk of developing
leprosy,28 since only a few positive individual became sick during 5 years of follow-up.
The ND-O-LID-1 assay can be easily performed by the addition of serum to the assay
device, therefore, it can be applied in resource-poor settings, where specialised personnel and
logistics are not available. Besides, this test was found to be useful for the detection of
multibacillary cases, which in the long term will help to reduce transmission of the disease.
This is a highly specific test, but it is not highly sensitive for early detection of leprosy in
household contacts and paucibacillary forms. In spite of that, the findings support the need of
stakeholders to continue promoting the concept of attaining zero transmission, measurable by
M. leprae infection. Therefore, the investment in longitudinal research to identify biomarkers
for the diagnosis of asymptomatic infected individuals, as well as for those at high risk of
developing leprosy, such as contacts, should be continued.
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